Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457498 | 0.92 | CA12 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5450873 | 0.90 | CA12 (0.43) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5462110 | 0.89 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5456742 | 0.88 | CA14 (0.36) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5454295 | 0.88 | CA14 (0.36) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5458010 | 0.87 | NPC1 (0.38) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL5456923 | 0.83 | IDO1 (0.43) | ALDH1A1SMN1; SMN2GLAHPGDALOX12 | |
| SCHEMBL5457125 | 0.82 | BRD4 (0.38) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5450895 | 0.82 | CA12 (0.37) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL14428375 | 0.80 | CA12 (0.49) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | CA12 1186/4885CA1 661/4885CA2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.